Eton Pharmaceuticals, Inc.

As of August 26, 2025, Eton Pharmaceuticals, Inc. has shifted to a bullish trend, supported by positive signals from MACD, Bollinger Bands, and moving averages, while outperforming the S&P 500 with a 1-year return of 212.35%.

As of August 8, 2024, Eton Pharmaceuticals, Inc. is considered risky and overvalued due to poor financial metrics, including a negative P/E ratio and high Price to Book Value, despite a strong stock performance.

As of August 8, 2024, Eton Pharmaceuticals, Inc. is considered overvalued and risky due to poor financial metrics, including a Price to Book Value of 18.47, an EV to EBITDA ratio of 464.26, and negative returns on capital and equity, alongside a significant decline in stock performance compared to the S&P 500.

As of June 9, 2025, the trend is mildly bullish due to positive daily moving averages, but caution is warranted from mildly bearish weekly MACD and KST indicators, alongside bearish weekly Bollinger Bands.

As of March 2022, the management team of Eton Pharmaceuticals, Inc. includes Dr. Norbert Riedel (Independent Chairman), Mr. Sean Brynjelsen (President and CEO), Mr. Mark Baum (Director), and independent directors Mr. Charles Casamento and Mr. Paul Maier. They oversee the company's strategic direction and operations.

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products. As of March 2025, it reported net sales of $17 million and a net loss of $2 million, with a market cap of approximately $365 million.

As of Jun 18, Eton Pharmaceuticals, Inc. has a market capitalization of 364.99 million and reported net sales of 48.32 million with a net profit of -4.58 million over the last four quarters. Shareholder's funds are 24.43 million, and total assets are 76.12 million as of Dec 24.